CELESTIAL

CELESTIAL

Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar Post Approval Registry

Study Design

  • Multi-center, prospective, non-randomized, FDA reviewed, observational study1
  • Designed to gather long-term safety and reliability data on BIOTRONIK’s Corox BP LV leads
  • 2,499 patients at 97 USA centers - This study is ongoing

Key Result

The CELESTIAL registry focuses primarily on the performance of Corox leads (n=2,499), however, the majority of patients received a CRT-D system including a Linox or Linoxsmart ICD lead (n=1,843)

Recent publication1 with results from the ongoing GALAXY and CELESTIAL studies demonstrate favorable lead survival probabilities

Clinical Relevance

  • Linox and Linoxsmart ICD leads are safe, reliable and infrequently associated with lead-related adverse events (AEs)
  • Estimated cumulative survival probability is favorable and well within industry standards
  • Scientifically sound analysis due to multi-center, high enrollment, prospective study design as well as adjudication of AEs by an independent panel of five EPs
  • Most extensive description of performance, safety and longevity of Linox ICD leads published to date
1° Endpoints
  • To evaluate the overall incidence of serious adverse events related to the Corox BP LV leads
  • To evaluate the incidence of each type of serious adverse event that contributes to the above point
2° Endpoints
  • Successful biventricular pacing in a BIOTRONIK CRT device at scheduled CELESTIAL registry follow-up through 5 years post-enrollment
  • Serious adverse event rates for SAEs excluded from primary safety endpoint through 5 years post-enrollment
  • Pacing threshold, sensing, and impedance measurements for Corox BP leads at scheduled CELESTIAL registry follow-up through 5 years post-enrollment
Clinical Sites
  • 99 centers, 78 active
Sample Size
  • 2,499 patients
Inclusion Criteria
  • Successfully implanted BIOTRONIK CRT system, including a Corox BP LV lead, from 7-180 days prior to enrollment
  • Able to understand the nature of the registry and give informed consent
  • Available for follow-up visits on a regular basis at the investigational site
  • Age greater than or equal to 18 years
Main Exclusion Criteria
  • Enrolled in any IDE clinical study
  • Planned cardiac surgical procedures or interventional measures within the next 6 months
  • Expected to receive a heart transplant within 1 year
  • Life expectancy less than 1 year
  • Presence of another life-threatening, underlying illness separate from their cardiac disorder
  • Pregnancy
Devices
  • Corox OTW BP, Corox OTW-S BP, Corox OTW-L BP in conjunction with a BIOTRONIK CRT-P or CRT-D
Reference no.
  • NCT00810264

Download Section

Long-Term Evaluation of Biotronik Linox and Linoxsmart Implantable Cardioverter Defibrillator Leads

Related Products

ICD Teaser

CRT Leads

More Information

BIOTRONIK offers high performance with safety in mind in the field of lead technology.

GALAXY study Teaser

GALAXY study

More Information

The GALAXY study, a multi-center, prospective FDA reviewed designed to monitor the real world performance of BIOTRONIK leads.

1 Good ED, Cakulev I, Orlov MV, Hirsh D, Similes J, Mohr K, Moll P, Bloom H; Long-Term Evaluation of Biotronik Linox and Linoxsmart Implantable Cardioverter Defibrillator Leads; J Cardiovasc Electrophysiol 2016 [epub]; DOI: 10.1111/jce.12971